Skip to main content
padlock icon - secure page this page is secure

In vitro activities of ferrochloroquine against 55 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs

Buy Article:

$52.00 + tax (Refund Policy)

The in vitro activities of ferrochloroquine, chloroquine, quinine, mefloquine, halofantrine, amodiaquine, artesunate, atovaquone, cycloguanil and pyrimethamine were evaluated against Plasmodium falciparum isolates from Senegal (Dielmo, Ndiop), using an isotopic micro-drug susceptibility test. The IC50 values for ferrochloroquine ranged from 0.55 to 28.2 nMand the geometric mean IC50 for the 55 isolates was 7.9 nM(95% CI, 6.5–9.7 nM). Ferrochloroquine was 35 times more active than chloroquine (35-fold greater against chloroquine-resistant isolates), quinine, mefloquine, amodiaquine, cycloguanil and pyrimethamine. Weak positive correlations were observed between the responses to ferrochloroquine and that to chloroquine, quinine, and amodiaquine, but not compulsorily predictive of cross-resistance. There was no significant correlation between the response to ferrochloroquine and that to mefloquine, halofantrine, artesunate, atovaquone, cycloguanil and pyrimethamine. Ferrochloroquine may be an important alternative drug for the treatment of chloroquine-resistant malaria.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Plasmodium falciparum; drug resistance; ferrochloroquine; in vitro susceptibility; malaria

Document Type: Original Article

Affiliations: 1: Unité de Parasitologie, Institut de Médecine Tropicale du Service de Santé des Armées, Le Pharo, Marseille, France, 2: Service d'Epidémiologie, Institut Pasteur, Dakar, Sénégal, 3: Centre Labusquière, Université de Bordeaux II, Bordeaux, France, 4: Institut de Recherche Pierre Fabre, Centre de Développement, Labège Innopole, France, 5: Laboratoire de Paludologie, IRD, Dakar, Sénégal

Publication date: March 1, 2002

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more